A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

BACKGROUND: Less than half of unselected metastatic cancer patients benefit from the immune checkpoint inhibitor (ICI) therapy. Systemic cancer-related inflammation may influence the efficacy of ICIs and thus, systemic inflammatory markers could have prognostic and/or predictive potential in ICI the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiainen, Satu, Nurmela, Veera, Selander, Tuomas, Turunen, Patrik, Pasonen-Seppänen, Sanna, Kettunen, Tiia, Kuittinen, Outi, Auvinen, Päivi, Rönkä, Aino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694914/
http://dx.doi.org/10.1186/s12885-023-11699-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694914/
http://dx.doi.org/10.1186/s12885-023-11699-0

Ejemplares similares